PriceTracker GLP-1

FDA record · 503B outsourcing facility

Apollo Care: FDA 503B outsourcing facility record

Apollo Care in Columbia, MO is on FDA's register of 503B outsourcing facilities. Registered since Sep 14, 2017; last FDA inspection Jul 28, 2026; Form 483 issued at that inspection: Yes; action FDA lists: Open. Register updated by FDA Sep 30, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA register read October 2026
Status: Registered since Sep 14, 2017; last FDA inspection Jul 28, 2026.

What FDA’s register states

FDA register entry for Apollo Care
FieldWhat FDA’s record statesSource
FacilityApollo CareFDA register
LocationColumbia, MOFDA register
First registeredSep 14, 2017FDA register
Most recent registrationDec 24, 2025FDA register
Last FDA inspectionJul 28, 2026FDA register
Form 483 issuedYesFDA register
Recall conductedNoFDA register
Action based on last inspectionOpenFDA register
Earlier compounding actionFDA notes at least one previous compounding inspection that resulted in a Form 483, warning letter or other actionFDA register
Intends to compound sterile drugs from bulkYesFDA register

Registration is a filing, not an approval.A Form FDA 483 lists what investigators observed; in FDA’s words it “does not constitute a final agency determination of whether any condition is in violation of the FD&C Act or any relevant regulations.” “Open” means FDA has not determined whether further action will be taken.

GLP-1 recalls by a firm of this name

  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0747-2026 · SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0748-2026 · SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0749-2026 · SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0750-2026 · SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0751-2026 · SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 M...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0752-2026 · SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0753-2026 · SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injectio...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0754-2026 · SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0755-2026 · SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0756-2026 · SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Onl...
  • Class II, ongoing, reported Aug 19, 2026Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0757-2026 · SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Onl...

Matched by name, from FDA’s enforcement reports (updated by FDA Sep 30, 2026). Every GLP-1 recall

Source

Copied from FDA’s Registered Outsourcing Facilities table ↗, updated by FDA Sep 30, 2026, read Oct 7, 2026. The table does not include State Board of Pharmacy actions. All 98 registered facilities